Microbial Fermentation CMO Market across Type of Biologic, Type of Microbial Expression System Used, Scale of Operation, End User and Key Geographical Regions: Industry Trends and Global Forecasts, 2020-2030
The microbial fermentation CMO market is expected to reach USD 4 billion in 2020 and anticipated to grow at a CAGR of 9% during the forecast period 2020-2030.
Traditional methods of microbial cell cultures have historically been the primary means for producing a diverse range of biologics, including peptide therapeutics, low molecular weight proteins like insulin, and cytokines. Roughly 60% of therapeutic recombinant proteins have been estimated to be made using microbial expression systems, particularly Escherichia coli. Presently, over 70 biologics approved by global regulatory authorities are manufactured through microbial fermentation. The rise of innovative biologics, such as antibody fragments and plasmid DNA used in cell and gene therapies as well as DNA vaccines, has led to a notable increase in demand for microbial-based production systems. Additionally, advancements in manufacturing technologies have reignited interest among drug developers in using microbial platforms to create complex biologics. Given the complexity of biologics development and production, drug developers are inclined to outsource segments of their microbial manufacturing operations to Contract Manufacturing Organizations (CMOs) that specialize in microbial fermentation. Since 2017, there has been a marked increase in outsourcing activities related to microbial fermentation. The market for microbial fermentation CMOs currently includes small, mid-sized, and large entities, offering comprehensive solutions ranging from early-stage process development to clinical and commercial-scale manufacturing, alongside regulatory compliance. Despite the established nature of this domain, more than 25 new contract microbial fermentation companies have emerged in the past decade.
To remain competitive, CMOs and Contract Development and Manufacturing Organizations (CDMOs) have actively pursued the acquisition of cutting-edge fermentation technologies and invested in expanding their capacity to meet the rising demand for innovative biologics. Furthermore, the COVID-19 pandemic is expected to offer significant business opportunities for microbial fermentation CMOs as innovator companies seek support in manufacturing potential vaccines and other therapeutic approaches. Projections for the long-term foresee substantial market growth in the microbial fermentation CMO sector during the forecast period.
Report Coverage
Traditional methods of microbial cell cultures have historically been the primary means for producing a diverse range of biologics, including peptide therapeutics, low molecular weight proteins like insulin, and cytokines. Roughly 60% of therapeutic recombinant proteins have been estimated to be made using microbial expression systems, particularly Escherichia coli. Presently, over 70 biologics approved by global regulatory authorities are manufactured through microbial fermentation. The rise of innovative biologics, such as antibody fragments and plasmid DNA used in cell and gene therapies as well as DNA vaccines, has led to a notable increase in demand for microbial-based production systems. Additionally, advancements in manufacturing technologies have reignited interest among drug developers in using microbial platforms to create complex biologics. Given the complexity of biologics development and production, drug developers are inclined to outsource segments of their microbial manufacturing operations to Contract Manufacturing Organizations (CMOs) that specialize in microbial fermentation. Since 2017, there has been a marked increase in outsourcing activities related to microbial fermentation. The market for microbial fermentation CMOs currently includes small, mid-sized, and large entities, offering comprehensive solutions ranging from early-stage process development to clinical and commercial-scale manufacturing, alongside regulatory compliance. Despite the established nature of this domain, more than 25 new contract microbial fermentation companies have emerged in the past decade.
To remain competitive, CMOs and Contract Development and Manufacturing Organizations (CDMOs) have actively pursued the acquisition of cutting-edge fermentation technologies and invested in expanding their capacity to meet the rising demand for innovative biologics. Furthermore, the COVID-19 pandemic is expected to offer significant business opportunities for microbial fermentation CMOs as innovator companies seek support in manufacturing potential vaccines and other therapeutic approaches. Projections for the long-term foresee substantial market growth in the microbial fermentation CMO sector during the forecast period.
Report Coverage
- The report extensively investigates the microbial fermentation Contract Manufacturing Organization (CMO) market, focusing on various parameters including the type of biologic, microbial expression systems utilized, operational scale, end-user segmentation, and key geographical regions.
- It conducts an in-depth analysis of factors such as market drivers, restraints, opportunities, and challenges influencing the growth trajectory. Additionally, it evaluates both the potential advantages and obstacles faced by stakeholders, offering insights into the competitive landscape for leading market players.
- Revenue forecasts for market segments across five major regions are provided, enabling a comprehensive understanding of market dynamics and regional variances.
- A comprehensive review is undertaken to explore the current landscape of microbial fermentation companies offering contract manufacturing services for biologics through microbial expression systems. This entails crucial details such as establishment year, company size, headquarters location, production facility details including numbers and locations, operational scale across preclinical, clinical, and commercial stages, types of biologics manufactured, microbial expression systems employed, fermenter types utilized, offered manufacturing services, and regulatory accreditations.
- Company competitiveness is analyzed regionally, taking into account establishment years, service portfolios, biologic types, expression systems, and strategic partnerships. Emphasis is placed on identifying leading players based on their experience and expertise.
- An examination of partnerships in microbial contract biomanufacturing since 2016 is conducted, focusing on partnership models, scale, biologic types, therapeutic areas, key market participants, and geographical reach. Furthermore, mergers and acquisitions between 2016-2020 are outlined, considering the number of acquisitions and geographic distribution.
- Expansion initiatives undertaken between 2016-2020 are evaluated, considering the nature of expansion, scale, biologics involved, and locations. Additionally, the report explores microbial manufacturing initiatives by prominent pharmaceutical players, detailing the number, year, and types of initiatives.
- A proprietary 2x2 representation method is utilized to assess existing competition and growth opportunities within emerging and established market segments. Profiles of key players in North America, Europe, and Asia Pacific encompass their service portfolios, capabilities, facilities, recent developments, and future prospects.
- Industry trends, drivers, challenges, and SWOT analysis are discussed comprehensively, elucidating their impact on microbial fermentation CMO market dynamics using a Harvey ball analysis.
- A case study is included for comparative analysis between large molecule and small molecule drug characteristics, outlining their respective manufacturing processes. Additionally, the report explores the implications of the COVID-19 outbreak on microbial contract biomanufacturing, detailing CMOs' initiatives to mitigate associated challenges.
- AGC Biologics
- Aldevron
- BioVectra
- Ology Bioservices
- Eurogentec
- Northway Biotechpharma
- Porton Biopharma
- EirGenix
- Etinpro
- Stelis Biopharma
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1 Chapter Overview
3.2. Overview of Biopharmaceuticals
3.3. Expression Systems Used for Biopharmaceutical Production
3.3.1. Microbial Expression Systems
3.3.1.1. Bacterial Expression Systems
3.3.1.2. Fungal Expression Systems
3.3.1.3. Yeast Expression Systems
3.3.2. Mammalian versus Microbial Expression Systems
3.4. Microbial Manufacturing Process
3.4.1. Cell Banking
3.4.2. Upstream Processing
3.4.3. Fermentation
3.4.4. Downstream Processing
3.5. Overview of Contract Manufacturing
3.6. Need for Outsourcing Microbial Biomanufacturing Operations
3.7. Commonly Outsourced Microbial Biomanufacturing Operations
3.8. Advantages and Risks Associated with Outsourcing Microbial Biomanufacturing
3.9. Key Considerations while Selecting a CMO Partner
3.10. Concluding Remarks
4. MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Microbial Contract Biomanufacturing Market: Overall Market Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Location of Headquarters
4.2.4. Analysis by Location of Manufacturing Facility
4.2.5. Analysis by Scale of Operation
4.2.6. Analysis by Type of Biologic
4.2.7. Analysis by Type of Expression System Used
4.2.8. Analysis by Type of Fermenter
4.2.9. Analysis by Type of Service(s) Offered
4.2.10. Analysis by Regulatory Accreditations / Certifications
4.3. Regional Analysis
4.3.1. Analysis by North America
4.3.2. Analysis by Europe
4.3.3. Analysis by Asia Pacific
4.3.4. Analysis by Middle East and North Africa
5. COMPANY COMPETITIVENESS ANALYSIS
5.1. Chapter Overview
5.2. Assumptions and Key Parameters
5.3. Methodology
5.4. Competitiveness Analysis
5.4.1. Competitiveness Analysis: Companies in North America
5.4.2. Competitiveness Analysis: Companies in Europe
5.4.3. Competitiveness Analysis: Companies in Asia Pacific
6. COMPANY PROFILES
6.1. Chapter Overview
6.2. Microbial Contract Biomanufacturers based in North America
6.2.1. AGC Biologics
6.2.1.1. Company Overview
6.2.1.2. Service Portfolio
6.2.1.3. Manufacturing Capabilities and Facilities
6.2.1.4. Recent Developments and Future Outlook
6.2.2. Aldevron
6.2.2.1. Company Overview
6.2.2.2. Service Portfolio
6.2.2.3. Manufacturing Capabilities and Facilities
6.2.2.4. Recent Developments and Future Outlook
6.2.3. BioVectra
6.2.3.1. Company Overview
6.2.3.2. Service Portfolio
6.2.3.3. Manufacturing Capabilities and Facilities
6.2.3.4. Recent Developments and Future Outlook
6.2.4. Ology Bioservices
6.2.4.1. Company Overview
6.2.4.2. Service Portfolio
6.2.4.3. Manufacturing Capabilities and Facilities
6.2.4.4. Recent Developments and Future Outlook
6.3. Microbial Contract Biomanufacturers Based in Europe
6.3.1. Eurogentec
6.3.1.1. Company Overview
6.3.1.2. Service Portfolio
6.3.1.3. Manufacturing Capabilities and Facilities
6.3.1.4. Recent Developments and Future Outlook
6.3.2. Northway Biotechpharma
6.3.2.1. Company Overview
6.3.2.2. Service Portfolio
6.3.2.3. Manufacturing Capabilities and Facilities
6.3.2.4. Recent Developments and Future Outlook
6.3.3. Porton Biopharma
6.3.3.1. Company Overview
6.3.3.2. Service Portfolio
6.3.3.3. Manufacturing Capabilities and Facilities
6.3.3.4. Recent Developments and Future Outlook
6.4. Microbial Contract Biomanufacturers Based in Asia Pacific
6.4.1. EirGenix
6.4.1.1. Company Overview
6.4.1.2. Service Portfolio
6.4.1.3. Manufacturing Capabilities and Facilities
6.4.1.4. Recent Developments and Future Outlook
6.4.2. Etinpro
6.4.2.1. Company Overview
6.4.2.2. Service Portfolio
6.4.2.3. Manufacturing Capabilities and Facilities
6.4.2.4. Recent Developments and Future Outlook
6.4.3. Stelis Biopharma
6.4.3.1. Company Overview
6.4.3.2. Service Portfolio
6.4.3.3. Manufacturing Capabilities and Facilities
6.4.3.4. Recent Developments and Future Outlook
7. RECENT PARTNERSHIPS
7.1. Chapter Overview
7.2. Partnership Models
7.3. Microbial Contract Biomanufacturers: Recent Partnerships
7.3.1. Analysis by Year of Partnerships
7.3.2. Analysis by Type of Partnership Model
7.3.3. Analysis by Scale of Operation
7.3.4. Analysis by Type of Biologic
7.3.5. Analysis by Focus Area
7.3.6. Analysis by Target Therapeutic Area
7.3.7. Analysis by Region
7.3.7.1. Country-Wise Distribution
7.3.7.2. Intercontinental and Intracontinental Agreements
7.3.8. Most Active Players: Analysis by Number of Partnerships
7.4. Microbial Contract Biomanufacturers: Mergers and Acquisitions
7.4.1. Analysis by Year of Merger / Acquisition
7.4.2. Analysis by Type of Acquisition
7.4.3. Regional Analysis
7.4.3.1. Continent-wise Distribution
7.4.3.2. Country-wise Distribution
7.4.3.3. Intercontinental and Intracontinental Deals
7.4.4. Most Active Players: Analysis by Number of Acquisitions
7.4.5. Analysis by Key Value Drivers
7.4.5.1. Analysis by Year of Acquisition and Key Value Drivers
8. RECENT EXPANSIONS
8.1. Chapter Overview
8.2. Microbial Contract Biomanufacturers: Recent Expansions
8.2.1. Analysis by Year of Expansion
8.2.2. Analysis by Type of Expansion
8.2.3. Analysis by Scale of Operation
8.2.4. Analysis by Type of Biologic
8.3. Geographical Analysis
8.3.1. Continent-wise Distribution
9. MICROBIAL FERMENTATION TECHNOLOGY PLATFORMS
9.1. Chapter Overview
9.2. Technology Platforms Commonly Used for Microbial Fermentation
9.3. Upcoming Platforms-General Technologies
10. ATTRACTIVENESS COMPETITION MATRIX
10.1. Chapter Overview
10.2. AC Matrix: An Overview
10.2.1. Strong Business Segment
10.2.2. Average Business Segment
10.2.3. Weak Business Segment
10.3. AC Matrix: Analytical Methodology
10.4. AC Matrix: Contract Manufacturing Scenario in North America
10.5. AC Matrix: Contract Manufacturing Scenario in Europe
10.6. AC Matrix: Contract Manufacturing Scenario in Asia Pacific and Middle East
11. MAKE VERSUS BUY DECISION MAKING FRAMEWORK
11.1. Chapter Overview
11.2. Assumptions and Parameter Definitions
11.2.1. Scenario
11.2.2. Scenario
11.2.3. Scenario
11.2.4. Scenario
11.3. Concluding Remarks
12. BIG PHARMA INITITATIVES IN MICROBIAL BIOMANUFACTURING
12.1. Chapter Overview
12.2. List of Microbial Biomanufacturing Initiatives of Big Pharma Players
12.2.1. Analysis by Number of Initiatives
12.2.2. Analysis by Year of Initiative
12.2.3. Analysis by Purpose of Initiative
12.2.4. Analysis by Type of Initiative
12.2.5. Analysis by Development Scale
12.2.6. Analysis by Type of Drug Molecule
12.2.7. Analysis by Type of Microbial Expression System Used
12.2.8. Analysis by Year of Initiative and Company
12.2.9. Analysis by Purpose of Initiative and Company
12.2.10. Geographical Analysis by Investment Made
12.3. Competitive Benchmarking of Big Pharma Players
12.3.1. Big Pharma Summary
13. CASE STUDY: COMPARISON OF SMALL MOLECULE AND LARGE
13.1. Chapter Overview
13.2. Small Molecule and Large Molecule Drugs / Therapies
13.2.1. Comparison of Key Characteristics
13.2.2. Comparison of Microbial Manufacturing Processes
13.2.2.1. Microbial Contract Manufacturers Providing Services for Small Molecules
13.2.3. Comparison of Key Microbial Manufacturing Challenges
14. MARKET SIZING AND OPPORTUNITY ANALYSIS
14.1. Chapter Overview
14.2. Key Assumptions and Forecast Methodology
14.3. Overall Microbial Contract Biomanufacturing Market, 2020-2030
14.3.1. Microbial Contract Biomanufacturing Market for APIs, 2020-2030
14.3.2. Microbial Contract Biomanufacturing Market for FDFs, 2020-2030
14.4. Microbial Contract Biomanufacturing Market, 2020, 2025 and 2030: Distribution by Type of Biologic
14.5. Microbial Contract Biomanufacturing Market, 2020, 2025 and 2030: Distribution by Type of Microbial Expression System Used
14.6. Microbial Contract Biomanufacturing Market, 2020, 2025 and 2030: Distribution by Scale of Operation
14.7. Microbial Contract Biomanufacturing Market, 2020, 2025 and 2030: Distribution by End User
14.8. Microbial Contract Biomanufacturing Market, 2020, 2025, 2030: Distribution by Key Geographical Regions
14.8.1. Microbial Contract Biomanufacturing Market in North America, 2020-2030
14.8.1.1. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Proteins
14.8.1.3. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Enzymes
14.8.1.4. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Growth Hormones
14.8.1.5. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Antibody based Drugs
14.8.1.6. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Other Biologics
14.8.1.7. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Bacterial Cell-based Expression Systems
14.8.1.8. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Yeast Cell-based Expression Systems
14.8.1.9. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Other Microbial Cell-based Expression Systems
14.8.1.10. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Commercial Operations
14.8.1.11. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Preclinical / Clinical Operations
14.8.1.12. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Small Companies
14.8.1.13. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Mid-sized Companies
14.8.1.14. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Large / Very Large Companies
14.8.2. Microbial Contract Biomanufacturing Market in Europe, 2020-2030
14.8.2.1. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Proteins
14.8.2.2. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Enzymes
14.8.2.3. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Growth Hormones
14.8.2.4. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Antibody based Drugs
14.8.2.5. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Other Biologics
14.8.2.6. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Bacterial Cell-based Expression Systems
14.8.2.7. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Yeast Cell-based Expression Systems
14.8.2.8. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Other Microbial Cell-based Expression Systems
14.8.2.9. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Commercial Operations
14.8.2.10. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Preclinical / Clinical Operations
14.8.2.11. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Small Companies
14.8.2.12. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Mid-sized Companies
14.8.2.13. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Large / Very Large Companies
14.8.3. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030
14.8.3.1. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Proteins
14.8.3.2. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Enzymes
14.8.3.3. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Growth Hormones
14.8.3.4. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Antibody based Drugs
14.8.3.5. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Other Biologics
14.8.3.6. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Bacterial Cell-based Expression Systems
14.8.3.7. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Yeast Cell-based Expression Systems
14.8.3.8. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Other Microbial Cell-based Expression Systems
14.8.3.9. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Commercial Operations
14.8.3.10. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Preclinical / Clinical Operations
14.8.3.11. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Small Companies
14.8.3.12. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Mid-sized Companies
14.8.3.13. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Large / Very Large Companies
14.8.3. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030
14.8.3.1. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Proteins
14.8.3.2. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Enzymes
14.8.3.3. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Growth Hormones
14.8.3.4. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Antibody based Drugs
14.8.3.5. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Other Biologics
14.8.3.6. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Bacterial Cell-based Expression Systems
14.8.3.7. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Yeast Cell-based Expression Systems
14.8.3.6. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Other Microbial Cell-based Expression Systems
14.8.3.7. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Commercial Operations
14.8.3.8. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Preclinical / Clinical Operations
14.8.3.9. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Small Companies
14.8.3.10. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Mid-sized Companies
14.8.3.11. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Large / Very Large Companies
14.8.3. Microbial Contract Biomanufacturing Market in Latin America, 2020-2030
14.8.3.1. Microbial Contract Biomanufacturing Market in Latin America, 2020-2030: Share of Proteins
14.8.3.2. Microbial Contract Biomanufacturing Market in Latin America, 2020-2030: Share of Enzyme
14.8.3.3. Microbial Contract Biomanufacturing Market in Latin America, 2020-2030: Share of Growth Hormone
14.8.3.4. Microbial Contract Biomanufacturing Market in Latin America, 2020-2030: Share of Antibody based Drug
14.8.3.5. Microbial Contract Biomanufacturing Market in Latin America, 2020-2030: Share of Other Biologics
14.8.3.6. Microbial Contract Biomanufacturing Market in Latin America, 2020-2030: Share of Bacterial Cell-based Expression Systems
14.8.3.7. Microbial Contract Biomanufacturing Market in Latin America, 2020-2030: Share of Yeast Cell-based Expression Systems
14.8.3.8. Microbial Contract Biomanufacturing Market in Latin America, 2020-2030: Share of Other Microbial Cell-based Expression Systems
14.8.3.9. Microbial Contract Biomanufacturing Market in Latin America, 2020-2030: Share of Commercial Operations
14.8.3.10. Microbial Contract Biomanufacturing Market in Latin America, 2020-2030: Share of Preclinical / Clinical Operations
14.8.3.11. Microbial Contract Biomanufacturing Market in Latin America, 2020-2030: Share of Small Companies
14.8.3.12. Microbial Contract Biomanufacturing Market in Latin America, 2020-2030: Share of Mid-sized Companies
14.8.3.13. Microbial Contract Biomanufacturing Market in Latin America, 2020-2030: Share of Large / Very Large Companies
15. IMPACT OF COVID-19 PANDEMIC ON MICROBIAL CONTRACT BIOMANUFACTURING MARKET
15.1. Chapter Overview
15.2. Current Options and Recuperative Initiatives of Key Players
15.2.1. KBI Biopharma
15.2.2. Lonza
15.2.3. Porton Pharma Solutions
15.2.4. Wacker Biotech
15.2.5. Wuxi AppTec
15.3. Impact on Microbial Contract Biomanufacturing Market Opportunity
16. SWOT ANALYSIS
16.1. Chapter Overview
16.2. Strengths
16.3. Weaknesses
16.4. Opportunities
16.5. Threats
16.6. Comparison of SWOT Factors
17. CONCLUSION
17.1. Chapter Overview
17.2. Key Takeaways
18. INTERVIEW TRANSCRIPTS
18.1. Chapter Overview
18.2. Meteoric Biopharmaceuticals
18.2.1. Company Snapshot
18.2.2. Interview Transcript: Gaurav Kaushik (Chief Executive Officer and Managing Director)
18.3. List Biological Laboratories
18.3.1. Company Snapshot
18.3.2. Interview Transcript: Debbie Pinkston (Vice President, Sales and Business Development)
18.4. Olon
18.4.1. Company Snapshot
18.4.2. Interview Transcript: Andrea Conforto (Sales and Marketing, Bioservices Director)
18.5. Luina Bio
18.5.1. Company Snapshot
18.5.2. Interview Transcript: Max Rossetto (General Manager, Business Development)
18.6. WACKER Biotech
18.6.1. Company Snapshot
18.6.2. Interview Transcript: Rob van Dijk (Business Development Manager)
19. APPENDIX 1: TABULATED DATA
20. APPENDIX 2: LIST OF COMPANIES AND ORGANISTIONS
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1 Chapter Overview
3.2. Overview of Biopharmaceuticals
3.3. Expression Systems Used for Biopharmaceutical Production
3.3.1. Microbial Expression Systems
3.3.1.1. Bacterial Expression Systems
3.3.1.2. Fungal Expression Systems
3.3.1.3. Yeast Expression Systems
3.3.2. Mammalian versus Microbial Expression Systems
3.4. Microbial Manufacturing Process
3.4.1. Cell Banking
3.4.2. Upstream Processing
3.4.3. Fermentation
3.4.4. Downstream Processing
3.5. Overview of Contract Manufacturing
3.6. Need for Outsourcing Microbial Biomanufacturing Operations
3.7. Commonly Outsourced Microbial Biomanufacturing Operations
3.8. Advantages and Risks Associated with Outsourcing Microbial Biomanufacturing
3.9. Key Considerations while Selecting a CMO Partner
3.10. Concluding Remarks
4. MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Microbial Contract Biomanufacturing Market: Overall Market Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Location of Headquarters
4.2.4. Analysis by Location of Manufacturing Facility
4.2.5. Analysis by Scale of Operation
4.2.6. Analysis by Type of Biologic
4.2.7. Analysis by Type of Expression System Used
4.2.8. Analysis by Type of Fermenter
4.2.9. Analysis by Type of Service(s) Offered
4.2.10. Analysis by Regulatory Accreditations / Certifications
4.3. Regional Analysis
4.3.1. Analysis by North America
4.3.2. Analysis by Europe
4.3.3. Analysis by Asia Pacific
4.3.4. Analysis by Middle East and North Africa
5. COMPANY COMPETITIVENESS ANALYSIS
5.1. Chapter Overview
5.2. Assumptions and Key Parameters
5.3. Methodology
5.4. Competitiveness Analysis
5.4.1. Competitiveness Analysis: Companies in North America
5.4.2. Competitiveness Analysis: Companies in Europe
5.4.3. Competitiveness Analysis: Companies in Asia Pacific
6. COMPANY PROFILES
6.1. Chapter Overview
6.2. Microbial Contract Biomanufacturers based in North America
6.2.1. AGC Biologics
6.2.1.1. Company Overview
6.2.1.2. Service Portfolio
6.2.1.3. Manufacturing Capabilities and Facilities
6.2.1.4. Recent Developments and Future Outlook
6.2.2. Aldevron
6.2.2.1. Company Overview
6.2.2.2. Service Portfolio
6.2.2.3. Manufacturing Capabilities and Facilities
6.2.2.4. Recent Developments and Future Outlook
6.2.3. BioVectra
6.2.3.1. Company Overview
6.2.3.2. Service Portfolio
6.2.3.3. Manufacturing Capabilities and Facilities
6.2.3.4. Recent Developments and Future Outlook
6.2.4. Ology Bioservices
6.2.4.1. Company Overview
6.2.4.2. Service Portfolio
6.2.4.3. Manufacturing Capabilities and Facilities
6.2.4.4. Recent Developments and Future Outlook
6.3. Microbial Contract Biomanufacturers Based in Europe
6.3.1. Eurogentec
6.3.1.1. Company Overview
6.3.1.2. Service Portfolio
6.3.1.3. Manufacturing Capabilities and Facilities
6.3.1.4. Recent Developments and Future Outlook
6.3.2. Northway Biotechpharma
6.3.2.1. Company Overview
6.3.2.2. Service Portfolio
6.3.2.3. Manufacturing Capabilities and Facilities
6.3.2.4. Recent Developments and Future Outlook
6.3.3. Porton Biopharma
6.3.3.1. Company Overview
6.3.3.2. Service Portfolio
6.3.3.3. Manufacturing Capabilities and Facilities
6.3.3.4. Recent Developments and Future Outlook
6.4. Microbial Contract Biomanufacturers Based in Asia Pacific
6.4.1. EirGenix
6.4.1.1. Company Overview
6.4.1.2. Service Portfolio
6.4.1.3. Manufacturing Capabilities and Facilities
6.4.1.4. Recent Developments and Future Outlook
6.4.2. Etinpro
6.4.2.1. Company Overview
6.4.2.2. Service Portfolio
6.4.2.3. Manufacturing Capabilities and Facilities
6.4.2.4. Recent Developments and Future Outlook
6.4.3. Stelis Biopharma
6.4.3.1. Company Overview
6.4.3.2. Service Portfolio
6.4.3.3. Manufacturing Capabilities and Facilities
6.4.3.4. Recent Developments and Future Outlook
7. RECENT PARTNERSHIPS
7.1. Chapter Overview
7.2. Partnership Models
7.3. Microbial Contract Biomanufacturers: Recent Partnerships
7.3.1. Analysis by Year of Partnerships
7.3.2. Analysis by Type of Partnership Model
7.3.3. Analysis by Scale of Operation
7.3.4. Analysis by Type of Biologic
7.3.5. Analysis by Focus Area
7.3.6. Analysis by Target Therapeutic Area
7.3.7. Analysis by Region
7.3.7.1. Country-Wise Distribution
7.3.7.2. Intercontinental and Intracontinental Agreements
7.3.8. Most Active Players: Analysis by Number of Partnerships
7.4. Microbial Contract Biomanufacturers: Mergers and Acquisitions
7.4.1. Analysis by Year of Merger / Acquisition
7.4.2. Analysis by Type of Acquisition
7.4.3. Regional Analysis
7.4.3.1. Continent-wise Distribution
7.4.3.2. Country-wise Distribution
7.4.3.3. Intercontinental and Intracontinental Deals
7.4.4. Most Active Players: Analysis by Number of Acquisitions
7.4.5. Analysis by Key Value Drivers
7.4.5.1. Analysis by Year of Acquisition and Key Value Drivers
8. RECENT EXPANSIONS
8.1. Chapter Overview
8.2. Microbial Contract Biomanufacturers: Recent Expansions
8.2.1. Analysis by Year of Expansion
8.2.2. Analysis by Type of Expansion
8.2.3. Analysis by Scale of Operation
8.2.4. Analysis by Type of Biologic
8.3. Geographical Analysis
8.3.1. Continent-wise Distribution
9. MICROBIAL FERMENTATION TECHNOLOGY PLATFORMS
9.1. Chapter Overview
9.2. Technology Platforms Commonly Used for Microbial Fermentation
9.3. Upcoming Platforms-General Technologies
10. ATTRACTIVENESS COMPETITION MATRIX
10.1. Chapter Overview
10.2. AC Matrix: An Overview
10.2.1. Strong Business Segment
10.2.2. Average Business Segment
10.2.3. Weak Business Segment
10.3. AC Matrix: Analytical Methodology
10.4. AC Matrix: Contract Manufacturing Scenario in North America
10.5. AC Matrix: Contract Manufacturing Scenario in Europe
10.6. AC Matrix: Contract Manufacturing Scenario in Asia Pacific and Middle East
11. MAKE VERSUS BUY DECISION MAKING FRAMEWORK
11.1. Chapter Overview
11.2. Assumptions and Parameter Definitions
11.2.1. Scenario
11.2.2. Scenario
11.2.3. Scenario
11.2.4. Scenario
11.3. Concluding Remarks
12. BIG PHARMA INITITATIVES IN MICROBIAL BIOMANUFACTURING
12.1. Chapter Overview
12.2. List of Microbial Biomanufacturing Initiatives of Big Pharma Players
12.2.1. Analysis by Number of Initiatives
12.2.2. Analysis by Year of Initiative
12.2.3. Analysis by Purpose of Initiative
12.2.4. Analysis by Type of Initiative
12.2.5. Analysis by Development Scale
12.2.6. Analysis by Type of Drug Molecule
12.2.7. Analysis by Type of Microbial Expression System Used
12.2.8. Analysis by Year of Initiative and Company
12.2.9. Analysis by Purpose of Initiative and Company
12.2.10. Geographical Analysis by Investment Made
12.3. Competitive Benchmarking of Big Pharma Players
12.3.1. Big Pharma Summary
13. CASE STUDY: COMPARISON OF SMALL MOLECULE AND LARGE
13.1. Chapter Overview
13.2. Small Molecule and Large Molecule Drugs / Therapies
13.2.1. Comparison of Key Characteristics
13.2.2. Comparison of Microbial Manufacturing Processes
13.2.2.1. Microbial Contract Manufacturers Providing Services for Small Molecules
13.2.3. Comparison of Key Microbial Manufacturing Challenges
14. MARKET SIZING AND OPPORTUNITY ANALYSIS
14.1. Chapter Overview
14.2. Key Assumptions and Forecast Methodology
14.3. Overall Microbial Contract Biomanufacturing Market, 2020-2030
14.3.1. Microbial Contract Biomanufacturing Market for APIs, 2020-2030
14.3.2. Microbial Contract Biomanufacturing Market for FDFs, 2020-2030
14.4. Microbial Contract Biomanufacturing Market, 2020, 2025 and 2030: Distribution by Type of Biologic
14.5. Microbial Contract Biomanufacturing Market, 2020, 2025 and 2030: Distribution by Type of Microbial Expression System Used
14.6. Microbial Contract Biomanufacturing Market, 2020, 2025 and 2030: Distribution by Scale of Operation
14.7. Microbial Contract Biomanufacturing Market, 2020, 2025 and 2030: Distribution by End User
14.8. Microbial Contract Biomanufacturing Market, 2020, 2025, 2030: Distribution by Key Geographical Regions
14.8.1. Microbial Contract Biomanufacturing Market in North America, 2020-2030
14.8.1.1. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Proteins
14.8.1.3. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Enzymes
14.8.1.4. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Growth Hormones
14.8.1.5. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Antibody based Drugs
14.8.1.6. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Other Biologics
14.8.1.7. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Bacterial Cell-based Expression Systems
14.8.1.8. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Yeast Cell-based Expression Systems
14.8.1.9. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Other Microbial Cell-based Expression Systems
14.8.1.10. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Commercial Operations
14.8.1.11. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Preclinical / Clinical Operations
14.8.1.12. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Small Companies
14.8.1.13. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Mid-sized Companies
14.8.1.14. Microbial Contract Biomanufacturing Market in North America, 2020-2030: Share of Large / Very Large Companies
14.8.2. Microbial Contract Biomanufacturing Market in Europe, 2020-2030
14.8.2.1. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Proteins
14.8.2.2. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Enzymes
14.8.2.3. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Growth Hormones
14.8.2.4. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Antibody based Drugs
14.8.2.5. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Other Biologics
14.8.2.6. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Bacterial Cell-based Expression Systems
14.8.2.7. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Yeast Cell-based Expression Systems
14.8.2.8. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Other Microbial Cell-based Expression Systems
14.8.2.9. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Commercial Operations
14.8.2.10. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Preclinical / Clinical Operations
14.8.2.11. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Small Companies
14.8.2.12. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Mid-sized Companies
14.8.2.13. Microbial Contract Biomanufacturing Market in Europe, 2020-2030: Share of Large / Very Large Companies
14.8.3. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030
14.8.3.1. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Proteins
14.8.3.2. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Enzymes
14.8.3.3. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Growth Hormones
14.8.3.4. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Antibody based Drugs
14.8.3.5. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Other Biologics
14.8.3.6. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Bacterial Cell-based Expression Systems
14.8.3.7. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Yeast Cell-based Expression Systems
14.8.3.8. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Other Microbial Cell-based Expression Systems
14.8.3.9. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Commercial Operations
14.8.3.10. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Preclinical / Clinical Operations
14.8.3.11. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Small Companies
14.8.3.12. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Mid-sized Companies
14.8.3.13. Microbial Contract Biomanufacturing Market in Asia Pacific, 2020-2030: Share of Large / Very Large Companies
14.8.3. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030
14.8.3.1. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Proteins
14.8.3.2. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Enzymes
14.8.3.3. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Growth Hormones
14.8.3.4. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Antibody based Drugs
14.8.3.5. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Other Biologics
14.8.3.6. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Bacterial Cell-based Expression Systems
14.8.3.7. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Yeast Cell-based Expression Systems
14.8.3.6. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Other Microbial Cell-based Expression Systems
14.8.3.7. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Commercial Operations
14.8.3.8. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Preclinical / Clinical Operations
14.8.3.9. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Small Companies
14.8.3.10. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Mid-sized Companies
14.8.3.11. Microbial Contract Biomanufacturing Market in Middle East and North Africa, 2020-2030: Share of Large / Very Large Companies
14.8.3. Microbial Contract Biomanufacturing Market in Latin America, 2020-2030
14.8.3.1. Microbial Contract Biomanufacturing Market in Latin America, 2020-2030: Share of Proteins
14.8.3.2. Microbial Contract Biomanufacturing Market in Latin America, 2020-2030: Share of Enzyme
14.8.3.3. Microbial Contract Biomanufacturing Market in Latin America, 2020-2030: Share of Growth Hormone
14.8.3.4. Microbial Contract Biomanufacturing Market in Latin America, 2020-2030: Share of Antibody based Drug
14.8.3.5. Microbial Contract Biomanufacturing Market in Latin America, 2020-2030: Share of Other Biologics
14.8.3.6. Microbial Contract Biomanufacturing Market in Latin America, 2020-2030: Share of Bacterial Cell-based Expression Systems
14.8.3.7. Microbial Contract Biomanufacturing Market in Latin America, 2020-2030: Share of Yeast Cell-based Expression Systems
14.8.3.8. Microbial Contract Biomanufacturing Market in Latin America, 2020-2030: Share of Other Microbial Cell-based Expression Systems
14.8.3.9. Microbial Contract Biomanufacturing Market in Latin America, 2020-2030: Share of Commercial Operations
14.8.3.10. Microbial Contract Biomanufacturing Market in Latin America, 2020-2030: Share of Preclinical / Clinical Operations
14.8.3.11. Microbial Contract Biomanufacturing Market in Latin America, 2020-2030: Share of Small Companies
14.8.3.12. Microbial Contract Biomanufacturing Market in Latin America, 2020-2030: Share of Mid-sized Companies
14.8.3.13. Microbial Contract Biomanufacturing Market in Latin America, 2020-2030: Share of Large / Very Large Companies
15. IMPACT OF COVID-19 PANDEMIC ON MICROBIAL CONTRACT BIOMANUFACTURING MARKET
15.1. Chapter Overview
15.2. Current Options and Recuperative Initiatives of Key Players
15.2.1. KBI Biopharma
15.2.2. Lonza
15.2.3. Porton Pharma Solutions
15.2.4. Wacker Biotech
15.2.5. Wuxi AppTec
15.3. Impact on Microbial Contract Biomanufacturing Market Opportunity
16. SWOT ANALYSIS
16.1. Chapter Overview
16.2. Strengths
16.3. Weaknesses
16.4. Opportunities
16.5. Threats
16.6. Comparison of SWOT Factors
17. CONCLUSION
17.1. Chapter Overview
17.2. Key Takeaways
18. INTERVIEW TRANSCRIPTS
18.1. Chapter Overview
18.2. Meteoric Biopharmaceuticals
18.2.1. Company Snapshot
18.2.2. Interview Transcript: Gaurav Kaushik (Chief Executive Officer and Managing Director)
18.3. List Biological Laboratories
18.3.1. Company Snapshot
18.3.2. Interview Transcript: Debbie Pinkston (Vice President, Sales and Business Development)
18.4. Olon
18.4.1. Company Snapshot
18.4.2. Interview Transcript: Andrea Conforto (Sales and Marketing, Bioservices Director)
18.5. Luina Bio
18.5.1. Company Snapshot
18.5.2. Interview Transcript: Max Rossetto (General Manager, Business Development)
18.6. WACKER Biotech
18.6.1. Company Snapshot
18.6.2. Interview Transcript: Rob van Dijk (Business Development Manager)
19. APPENDIX 1: TABULATED DATA
20. APPENDIX 2: LIST OF COMPANIES AND ORGANISTIONS
